CD49b/CD61 Receptor: A Critical Regulator of Cell Adhesion and Migration

Target Name: Integrin alpha2beta3 Receptor

NCBI ID: P22884

Integrin alpha2beta3 Receptor

Other Name(s): CD49b/CD61

CD49b/CD61 Receptor: A Critical Regulator of Cell Adhesion and Migration

Integrin alpha2beta3 receptor (CD49b/CD61) is a protein that is expressed in various cell types, including platelets, endothelial cells, and Leyman cells. It is a member of the integrin family of transmembrane proteins, which are involved in cell-cell and cell-extracellular matrix interactions. CD49b is a type I transmembrane protein that consists of an intracellular loop region, a transmembrane region, and an extracellular region. CD61 is a type II transmembrane protein that is similar to CD49b but with a different terminal region.

The CD49b/CD61 receptor is involved in many different cellular processes, including cell adhesion, migration, and invasion. It is a critical receptor for many different types of cancer, including breast, ovarian, and colorectal cancer. It is also a potential drug target for these cancers, as inhibition of the CD49b/CD61 receptor has been shown to be effective in preclinical studies.

The CD49b/CD61 receptor is composed of four transmembrane domains: an intracellular loop region, a transmembrane region, an extracellular region, and a cytoplasmic region. The intracellular loop region is the region that interacts with the cytoskeleton and includes a unique fenestration domain that is involved in the regulation of cell adhesion. The transmembrane region includes a transmembrane domain and a cytoplasmic domain. The cytoplasmic domain is the region that interacts with the cytosol and includes a unique region that is involved in the regulation of cell survival.

CD49b is a 21-kDa protein that consists of an intracellular loop region, a transmembrane region, and an extracellular region. The intracellular loop region is the region that interacts with the cytoskeleton and includes a unique fenestration domain that is involved in the regulation of cell adhesion. The transmembrane region includes a transmembrane domain and a cytoplasmic domain. The cytoplasmic domain is the region that interacts with the cytosol and includes a unique region that is involved in the regulation of cell survival.

CD61 is a 24-kDa protein that is similar to CD49b but with a different terminal region. It is also involved in cell adhesion and migration.

CD49b/CD61 receptor is involved in many different cellular processes, including cell adhesion, migration, and invasion. It is a critical receptor for many different types of cancer, including breast, ovarian, and colorectal cancer.

CD49b/CD61 receptor is also a potential drug target for these cancers, as inhibition of the CD49b/CD61 receptor has been shown to be effective in preclinical studies.

In conclusion, Integrin alpha2beta3 receptor (CD49b/CD61) is a critical regulator of cell adhesion, migration and invasion. It is a potential drug target for many different types of cancer and has been shown to be involved in the regulation of these processes in preclinical studies. Further research is needed to fully understand the role of the CD49b/CD61 receptor in cancer progression and the development of new cancer therapies.

Protein Name: Integrin Alpha2beta3 Receptor

The "Integrin alpha2beta3 Receptor Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Integrin alpha2beta3 Receptor comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets